InsiderDB

Lobbying disclosures · Lobbying report

ABBV: third_quarter 2026 lobbying report

Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act. Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.

Follow ABBV
Became public
Oct 8, 2026, 4:15 PM EDT
Event / period date
Not stated
Collected
Nov 9, 2026, 9:38 AM EST

Why this is connected

Exact legal-name match: AbbVie Inc. (https://www.sec.gov/Archives/edgar/data/1551152/).

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/7f32973c-aa87-41c1-a9f4-7a0f6df7f250/","filing_uuid":"7f32973c-aa87-41c1-a9f4-7a0f6df7f250","filing_type":"RA","filing_type_display":"Registration - Amendment","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/7f32973c-aa87-41c1-a9f4-7a0f6df7f250/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jonathon Jones, Partner","dt_posted":"2026-10-08T16:15:44-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"750 9th Street NW","registrant_address_2":"Suite 501","registrant_different_address":null,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":20744,"url":"https://lda.gov/api/v1/registrants/20744/","house_registrant_id":31587,"name":"TIBER CREEK GROUP","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GRACE BAUM","contact_telephone":"+1 202-381-6896","dt_updated":"2026-07-20T13:07:00.819992-04:00"},"client":{"id":127199,"url":"https://lda.gov/api/v1/clients/127199/","client_id":1005472,"name":"ABBVIE INC.","general_description":"Global biopharmaceutical company.","client_government_entity":false,"client_self_select":false,"state":"IL","state_display":"Illinois","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2013-02-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":107185,"prefix":null,"prefix_display":null,"first_name":"COREY","nickname":null,"middle_name":null,"last_name":"MALMGREN","suffix":null,"suffix_display":null},"covered_position":"Sen. Bill Nelson, Deputy Legislative Director & Health Counsel (2015-2018); Rep. Sandy Levin, Legislative Counsel (2013-2015), Legislative Correspondent, Staff Assistant (2008-2009); House Committee on Ways and Means, Legal Clerk/Intern (2010).","new":true},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Sen. Tom Carper (2001-2006).","new":true},{"lobbyist":{"id":143334,"prefix":"mr","prefix_display":"MR.","first_name":"DANIEL","nickname":null,"middle_name":"HOWARD","last_name":"ZAWITOSKI","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Scott Peters (2018-2023); Legislative Director, Rep. Scott Peters (2015-2018); Legislative Assistant, Rep. Scott Peters (2014-2015); Legislative Correspondent, Rep. Scott Peters (2013-2014).","new":true}],"government_entities":[]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":107185,"prefix":null,"prefix_display":null,"first_name":"COREY","nickname":null,"middle_name":null,"last_name":"MALMGREN","suffix":null,"suffix_display":null},"covered_position":"Sen. Bill Nelson, Deputy Legislative Director & Health Counsel (2015-2018); Rep. Sandy Levin, Legislative Counsel (2013-2015), Legislative Correspondent, Staff Assistant (2008-2009); House Committee on Ways and Means, Legal Clerk/Intern (2010).","new":true},{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Sen. Tom Carper (2001-2006).","new":true},{"lobbyist":{"id":143334,"prefix":"mr","prefix_display":"MR.","first_name":"DANIEL","nickname":null,"middle_name":"HOWARD","last_name":"ZAWITOSKI","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Rep. Scott Peters (2018-2023); Legislative Director, Rep. Scott Peters (2015-2018); Legislative Assistant, Rep. Scott Peters (2014-2015); Legislative Correspondent, Rep. Scott Peters (2013-2014).","new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Price change after we could observe it

+0.37% ABBV

Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.

Congressional trading in ABBV

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.